ArticleMolecular biology reports2026
Histidine, carnosine, and ergothioneine attenuate pyrazole/LPS-induced hepatotoxicity through modulation of CYP2E1, Nrf2, and NF-κB signaling in mice.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
BACKGROUND/
aimCytochrome P450 2E1 (CYP2E1) is key in liver damage from oxidative stress. The pyrazole (Pyr)- and lipopolysaccharide (LPS)- induced mouse model, which combines CYP2E1 induction with endotoxemia, is useful for studying liver protection. This study assessed how imidazole compounds (histidine, carnosine, and ergothioneine) affect Pyr + LPS-induced liver injury and the mechanisms involved.
methodsMale C57BL/6J mice received histidine (250 mg/kg, i.p.), carnosine (250 mg/kg, i.p.), histidine + carnosine (250 mg/kg each, i.p.), or ergothioneine (70 mg/kg, oral) for 10 consecutive days. Pyrazole (150 mg/kg, i.p.) was administered on days 8 and 9, followed by LPS (10 mg/kg, i.p.) on day 10. Serum ALT and AST activities, hepatic oxidative stress markers (ROS, TBARS, AOPP), antioxidant parameters (GSH, SOD, GSH-Px, FRAP), CYP2E1 protein levels, nitric oxide metabolites (NOx), and mRNA expressions of Nrf2, HO-1, NF-κB, TNF-α, and IL-6 were determined. Histopathological examination was also performed.
resultsPyr + LPS administration significantly elevated serum ALT and AST levels, hepatic CYP2E1, oxidative stress markers, and NOx, while reducing antioxidant defenses. NF-κB, TNF-α, IL-6, and HO-1 mRNA expressions were elevated. Pre-treatment with all imidazole compounds significantly attenuated these alterations, reduced CYP2E1 levels, and further upregulated HO-1 expression. The combination of histidine and carnosine also increased Nrf2 mRNA expression. Histopathological findings corroborated the biochemical results.
conclusionHistidine, carnosine, and ergothioneine protected against Pyr + LPS-induced hepatic injury and reduced oxidative stress. These effects were accompanied by alterations in CYP2E1 protein levels and NF-κB/Nrf2/HO-1-related gene expression; however, further studies are needed to clarify the underlying mechanisms.
Indexed as
Identifiers
42455220What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.